glp 1 and dpp4 dpp-4_inhibitors [TUSOM 𝐋𝐚𝐭𝐞𝐬𝐭 𝐩𝐨𝐬𝐢𝐭𝐢𝐨𝐧 𝐨𝐟 𝐃𝐏𝐏-𝟒 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬

Background The intent of transitional device pass-through payment, as implemented at 42 CFR 419.66, is to facilitate access for beneficiaries to the advantages of new and truly innovative devices by allowing for adequate payment for these new devices while the necessary cost data is collected to incorporate the costs for these devices into the procedure APC rate (66 FR 55861)

Most importantly, consult with a provider who has experience working with CJC-1295 and Ipamorelin

Pain Relief: The peptide may also have analgesic (pain-relieving) effects, providing relief from chronic pain

Not a substitute for medical care.

The post cites the SUSTAIN and SELECT trials, which it says showed adverse event rates comparable to placebo in many cases